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Abstract
Objectives With 70% of care home residents experiencing a medication error
every day in the UK, better multi-professional working between medical practition-
ers, pharmacists and care homes was recommended. The aim of this study was to
determine the effectiveness (falls reduction) and cost-effectiveness, of a multi-pro-
fessional medication review (MPMR) service in care homes for older people.
Method A total of care homes in the East of England were cluster randomised
to ‘usual care’ or two multi-professional (General practitioner, clinical pharma-
cist and care homes staff) medication reviews during the 12-month trial period.
Target recruitment was 900 residents with 10% assumed loss to follow-up. Co-
primary outcome measures were number of falls and potentially inappropriate
prescribing assessed by the Screening Tool of Older Persons Prescriptions.
Key findings A total of 826 care home residents were recruited with 324 lost
to follow-up for at least one primary outcome measure. The mean number of
falls per resident per annum was 3.3 for intervention and 3.0 for control
(P = 0.947). Each resident was found to be prescribed 0.69 (intervention) and
0.85 (control) potentially inappropriate medicines after 12 months (P = 0.046).
No significant difference identified in emergency hospital admissions or deaths.
Estimated unadjusted incremental mean cost per resident was £374.26 higher
in the intervention group.
Conclusions In line with other medication review based interventions in care
homes, two MPMRs improved medication appropriateness but failed to
demonstrate improvements in clinical outcomes. From a health system perspec-
tive costs where estimated to increase overall and therefore a different model of
medicines management is required.
Background
As westernised populations age then the number of older
persons residing in care homes is anticipated to increase
and provide an additional challenge to the delivery of pri-
mary care services.[1] Older people residing in care homes
frequently have complex medical conditions resulting in
polypharmacy and a subsequent increase in the risk of
medication errors.[2,3] These include the use of medicines
which are no longer indicated; negative interactions with
concurrent medication; sub-optimal dosing; inadequate
monitoring; and inappropriate therapy duration.[4]
Consequently, not only are there significant costs associ-
ated with high levels of medication use, much of which
may be unnecessary, there are additional avoidable costs
resulting from avoidable iatrogenic disease.
The predominant strategy to address concerns regard-
ing problematic polypharmacy has been the use of a phar-
macists to perform medication reviews.[5] Whilst
researchers have repeatedly shown that pharmacists pro-
viding medication review services in care homes are effec-
tive at rationalising therapy[6-8] to date this model of care
has failed to demonstrate significant benefits on resident
orientated outcomes e.g. falls, hospitalisations or
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mortality.[4,5,9] The Cochrane review regarding interven-
tions to optimise prescribing in older persons in care
homes, recommended that further higher quality research
surrounding medication review in care homes to deter-
mine clinical effectiveness was required.[4]
It is no longer sufficient to demonstrate service effec-
tiveness in isolation, evidence for cost-effectiveness is also
required to increase the chances of adoption. A relatively
small-scale cluster randomised trial performed in North-
ern Ireland focussed on pharmacist review of psychoactive
medicines in nursing home residents found that the ser-
vice was likely to be cost-effective.[10] Similarly, a non-
randomised concurrent controlled study found that medi-
cation review by pharmacists was likely to be cost-effec-
tive in Spain once quality of life scores were adjusted for
baseline, but less likely to be so when they were not.[11]
Consequently, there is also a need for greater evidence
regarding the value of pharmacist provision of general
medication review services to care homes.
Following the Care Homes Use of Medicines Study
(CHUMS) report in the UK, where 70% of residents were
found to experience at least one medication error each
day,[2] a multi-professional approach (joint working
between general practitioner (GP), care home and phar-
macist) was recommended nationally to improve medici-
nes management generally.[12] The aim of this study
therefore was to determine the clinical and cost-effective-
ness of a multi-professional medication review (MPMR)
service in care homes for older people.
Method
Study design and participants
Cluster randomised controlled trial of a MPMR per-
formed at 0 and 6 month in care homes in two counties
in eastern England with falls and medication appropriate-
ness as co-primary outcome measures. Trial design has
been previously published.[13]
Ethical approval was granted by the National Research
Ethics Committee East of England – Norfolk (09/H0310/
96). The trial was registered as ISRCTN90761620.
Recruitment
Recruitment was a two stage process with initial consent
sought from the GP(s) and a subsequent approach made
to their associated care homes which met the following
criteria.
Inclusion criteria:
• Providing care for residents with an average age
>65 years
Exclusion criteria:
• already received a medication review service from the
primary care organisation in the last 6 months
• receiving ongoing medication services from a commu-
nity geriatrician
• subject to investigation of the safeguarding of vulnera-
ble adults.
All residents within the recruited homes received the
intervention unless they were self-medicating or registered
in the home for respite care. With randomisation at the
level of care home and no additional data collected which
was not part of routine practice, it was deemed acceptable
not to obtain individual resident consent for inclusion
within the trial.
Randomisation and masking
An independent statistician randomised the recruited
homes to intervention or control. Care homes were strati-
fied according to size (small, medium or large) and resi-
dent mix (residential, nursing or mixed) and location
(Norfolk or Cambridgeshire). Homes were allocated (to
intervention or control) using minimisation by the ‘Vari-
ance method’ of Pocock and Simon,[14] to achieve
approximate balance with respect to stratifying variables.
It was not possible to blind care homes, pharmacists or
GPs to allocation due to the nature of the intervention.
Intervention
Delivery of the intervention and data collection took place
between April 2011 and April 2012. Intervention homes
received a MPMR at the care home, from a team consist-
ing of a clinical pharmacist (with a postgraduate diploma
in clinical or general pharmacy practice), GP and care
home member of staff responsible for medication, with
preparation undertaken by a pharmacy technician. To
ensure implementation of interventions from the first
review, monitor outcomes and address any new pharma-
ceutical issues a second MPMR was provided 6 months
after the initial review.
The outcome of the meeting was an agreed medicines
related action plan with the pharmacy technician updat-
ing GP records and communicating this to the pharmacy
responsible for supplying the medicines. Wherever possi-
ble, medication changes were discussed with the resident
and/or family by the care home staff or GP prior to the
change being made. Further details of the intervention are
available from the protocol.[13]
Control
Homes allocated to the control arm continued to receive
their usual care which varied from as much as weekly
structured visits to the care home, to ad hoc visits when
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patients needed to be seen by the GP. Visits by other
health and social care professionals were undertaken as
required. To support engagement by control homes, the
intervention was offered to the control homes at the end
of data collection.
Follow-up
Follow-up was determined as being 12 months from the
date of first medication review in intervention homes and
12 months from an equivalent period (to intervention
homes) after allocation in control homes.
Outcomes
All data were extracted from routine medical or care
home records by the pharmacy technician, but given their
involvement in the intervention it was not possible to
blind them during the data extraction process. Hospital
Episode Statistics (HES) data were provided by the pri-
mary care organisation to the pharmacy technicians at the
end of data collection.
Our co-primary outcome were falling and potentially
inappropriate prescribing. Whilst the main aim of medi-
cation review is to improve the quality of prescribing and
Screening Tool of Older Persons Prescriptions (STOPP)/
START criteria are used to measure this,[15] we recognised
that these were a measure of process and not patient ori-
entated. Falls were therefore additionally selected as our
clinical primary outcome measure. An intervention of a
similar nature demonstrated a significant reduction in this
outcome as one of their secondary outcome measures.[3]
Furthermore, with recognised overuse of medicines
related to falls in care homes[16,17] it would be reasonable
to assume that an intervention to rationalise therapy
would reduce this outcome.
Falls were extracted from government mandated and
defined care home falls records. Nature and severity of fall
were not recorded. ‘Potentially inappropriate prescrip-
tions’ were identified by a clinical pharmacist independent
of the intervention and blinded to group allocation using
the Screening Tool for Older Persons’ Potentially Inap-
propriate Prescriptions (STOPP criteria)[15] and used to
calculate the number of potentially inappropriate medici-
nes (PIMs) per resident at 12 months and 6 months as a
secondary outcome measure. Emergency hospital admis-
sions were extracted from HES provided by the primary
care organisation and mortality data were obtained from
GP practice records. In addition, details of all recommen-
dations arising from the medication review meetings were
recorded, together with data on the time taken to deliver
the various aspects of the intervention (organisation,
preparation, review meetings and follow-up actions).
Statistical analysis
All analyses were conducted at the individual-level using
random-effects models, we analysed data according to
randomisation group, irrespective of whether or not the
residents received the intervention as planned (intention
to treat principle). STATA version 11/SE with statistical
significance at the 5% level was used for all analyses.
Number of falls was analysed via a random-effects Pois-
son regression model at the individual-level with fixed
covariates of home size (small, medium or large); resi-
dent-type (residential or nursing) and location (Cam-
bridgeshire or Norfolk), with the random effect as the
care home. An offset of the number of days ‘at risk’ was
used in order to allow for censoring due to death or other
causes. The difference between intervention and control
arms was expressed as the rate ratio which is the ratio of
means. This is a common approach for the analysis of
count data in cluster randomised trials.[18] A sensitivity
analysis was conducted additionally adjusting for gender,
age and the number of baseline medications on the rec-
ommendation of the TMG who felt that these might be
predictive of the number of falls. Due to large number of
individuals with zero falls, a negative binomial model was
also fitted to the data. These results were similar to the
Poisson regression model.
Number of PIMs at 12 months was analysed using the
same approach as the number of falls but, in addition,
the baseline number of drugs which matched the STOPP
criteria was also included as a covariate.
The same process was repeated for secondary outcomes
measures: number of PIMs at 6 months and number of
emergency hospital admissions. The difference between
treatment groups was expressed as the rate ratio.
A Cox proportional hazards model analysed the time
to death with the same covariates as above using a robust
standard error to account for clustering.
Subgroup effects of resident type and care home size
were investigated by including an interaction term with
the intervention in the above models.
Sample size
The study was powered to detect a difference in the num-
ber of falls of 0.59, it was estimated that a sample of 450
residents per arm was required. This was considered a
clinically important difference based on similar previous
research[3] in a similar population which showed that
medication review services can reduce the average number
of falls per patient over a 6 month period by 0.59 (confi-
dence interval: 0.49 to 0.70), with a variance of four.[3]
Assuming the intra-cluster correlation coefficient is 0.02
and an average of 30 residents per home, the design effect
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is 1.58[19] requiring a total of 824 patients (412 in each
arm).
The aim was to recruit 30 homes with an average of 30
residents in order to allow for approximately 10% loss to
follow-up (e.g. due to death or moving home).
Economic analysis
All health care resource use was recorded from the care
home records. The average number of days between allo-
cation (T0) and first intervention visit (T1) in the inter-
vention arm, was used as the time period between T0 and
T1 in the control arm. At T0 pharmacy technicians
recorded resident identity but did not review medical
records to avoid any professional obligation to recom-
mend interventions. All data collection in the control
homes occurred 12 months after the calculated T1 point.
Data were extracted from the GP and care home records.
A within-trial economic analysis compared the costs
and clinical effectiveness (in terms of falls rate per resi-
dent per year) in the intervention (MPMR) and usual
care groups from the perspective of the UK National
Health Service (NHS) and Personal Social Services. A
micro-costing analysis approach was used to identify,
measure and value each input into the provision of the
MPMR intervention.[20] Resource use was extracted by
primary care pharmacy team staff from GP records (pri-
mary and community care, and medication use) and HES
(secondary care including emergency care) for the whole
12 month period. We attached published unit costs (UK
£2012) to individual-level quantities of resource use and
estimated the mean cost per participant incorporating the
cost of the intervention and wider healthcare resource use
(primary care, community care, secondary care and medi-
cations). An incremental analysis comparing the mean
cost and mean fall rate per resident per year was con-
ducted. This was an unadjusted analysis because we were
unable to collect baseline resource use data in control
homes. Neither costs nor outcomes were discounted
reflecting the 12-month study timeframe. All costs were
valued in UK pounds sterling for 2012.
Results
Figure 1 shows the flow of participants. A total of 51 GP
practices were approached, of which 25 (49%) consented,
9 (18%) declined and 17 (33%) did not respond to the
invitation. A total of 41 care homes associated with con-
senting GP practices were approached. 31 (76%) con-
sented, 5 (12%) declined and 5 (12%) did not respond.
One home was subsequently excluded after allocation to
treatment but before baseline data collection due to inves-
tigation by government agency regarding quality of care.
The other 30 care homes allocated to treatment remained
in the study until completion.
The trial recruited from January to December 2011
meeting the sample size number of participants with 15
care homes allocated to each of the intervention and con-
trol arms. There were 381 intervention participants and
445 control participants, with an average of 25.40 (stan-
dard deviation 11.06) individuals per cluster in the inter-
vention group and 29.67 (10.60) individuals per cluster in
the control group. 324 (39.2%) participants were lost to
follow-up for determination of PIMS at 12 months, 86%
of which was due to death.
Baseline characteristics for the two groups are reported
in Table 1, the intervention group were prescribed more
medications on average than the control group, a mean
difference of 1.7 medications. The control group included
more nursing home patients (29.7%) compared to the
intervention group (16.8%).
There were no significant differences between the treat-
ment groups for our falls outcome with a rate ratio of
1.01 (95% CI, 0.74 to 1.38, P = 0.947). The results were
similar when adjusted for gender, age and number of
medications; or when a negative binomial model was
used. However, the intervention did reduced PIMs by
almost 20% (RR 0.82, 95% CI 0.67 to 1.00), at 12 months
(Table 2).
In terms of secondary outcomes, there was no differ-
ence in emergency hospital admissions, rate ratio 1.18
(95% CI, 0.85 to 1.63, P = 0.322) or time until death
(HR 0.98, 95% CI 0.72 to 1.31, P = 0.868). No serious
adverse events were reported during the conduct of the
trial.
The results of the health economics analysis fall into
intervention costs, the 12-month wider resource use esti-
mates and overall cost-effectiveness results (Table 3). In
terms of the intervention costs the mean (SD; 95% CI)
cost per resident of the MPMR intervention was £104.08
(50.91; 98.72 to 109.45), such that the overall cost of pro-
viding the intervention to all 348 intervention home resi-
dents was £36 221.29 (95% CI 32 810.81 to
39 631.77).[20]
For 12-month wider resource use estimates, the unad-
justed mean (SD) cost per resident of wider health service
costs (primary care, community care (e.g. physiotherapy
and occupational therapy), secondary care (A&E, outpa-
tients and emergency admissions only), medications) were
£2210.64 (2479.73) in the intervention group and
£1940.46 (2323.36) in the usual care group. This gave a
mean (95% CI) difference of £270.18 (65.99 to 606.35).
[A table of unit costs provided as Table S1.
The estimated unadjusted overall (intervention costs
plus wider costs) mean (SD) cost per resident in the
intervention group was £2314.73 (2492.30) compared to
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£1940.47 (2323.36) when intervention costs were added
to the wider costs resulting in a mean difference of
£374.26 (95% CI 37.29 to 711.24).
Therefore, the overall result of the economic evaluation
is that the intervention group had both higher costs and
a higher falls rate per person per year. As a consequence,
it is estimated that the intervention is dominated by usual
care and would not be considered cost-effective.
Discussion
Whilst this cluster randomised controlled trial demon-
strated a reduction in potentially inappropriate prescrip-
tions when using MPMRs it did not demonstrate a
reduction in the number of falls. Furthermore, no
improvements in the secondary outcome measures of hos-
pitalisation or mortality were seen and the cost of deliver-
ing the intervention was unlikely to be justified by
reduction in the cost of healthcare resource utilisation.
Indeed, resource utilisation appeared to increase.
As a cluster randomised controlled trial across two
counties, involving many care homes, carefully delivered
with good quality data collection, the evidence provided
by this study can be considered to be reasonably robust.
However, there were several weaknesses, including higher
than anticipated losses to follow-up affecting our final
sample size, and some baseline differences between the
two groups. In terms of sample size, we had a target of
Figure 1 Flow of care homes and residents through the CAREMED trial.
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900 residents anticipating 10% losses to follow-up. The
realised sample size was 826 with just over 30% loss to
follow-up, mainly due to mortality, and this was greater
than the 10% we anticipated. Falls were however recorded
from randomisation until the end of the study or the
time of death. Consequently, the study was ultimately
adequately powered to detect a difference in falls.
Baseline differences suggested that the intervention
group were prescribed more medicines and had a lower
proportion of nursing home residents. However, adjusting
for these variables did not affect the result. In addition, in
terms of outcomes, there were no patient-reported out-
comes (e.g. quality of life) – though it should be noted
that collecting such outcomes would have been very chal-
lenging given the cognitive state of the majority of partici-
pants. It was not possible to collect baseline values of all
outcomes which may have resulted in imbalanced groups,
however as the allocation in randomised we do not
believe that this would bias the comparison.
Finally, the STOPP tool[15] was not designed as an
objective outcome measure but as a clinical tool and
therefore requires some level of clinical interpretation.
Whilst we blinded the independent assessor to allocation,
the quality of this outcome measure is somewhat limited.
Previous studies of pharmacists performing medication
reviews in care homes have demonstrated improvements
in some process measures.[3,21-24] However, in the United
Kingdom, only the study by Zermansky et al. demon-
strated a reduction in falls as a secondary outcome mea-
sure. Our study utilised a more intensive intervention
(two medication reviews) and follow-up, but failed to
replicate that result. The result shown by Zermansky et al.
may have been a false positive resulting from testing a
number of outcome measures or that the more generaliz-
able team approach cannot replicate the results of one
highly skilled pharmacist.
Importantly, prescribing patterns in care homes seen at
the time of the Zermansky trial potentially increased the
likelihood of falls and subsequent prescribing guidance[25]
may have reduced the opportunity for decreasing falls as
a result of iatrogenic disease. Indeed, over the last few
years, there has been a concerted effort to reduce antipsy-
chotic prescribing in care homes[26] and these are known
to increase the likelihood of falls in the frail elderly. Falls
Table 1 Baseline characteristics
Control
(n = 445)
Mean (SD or %)
Intervention
(n = 381)
Mean (SD or %)
Age 86.0 (8.5) 88.4 (6.5)
Number of falls at T0a 1.5 (3.6) 1.9 (5.2)
STOPP criteria at T1b 0.7 (1.0) 0.8 (1.0)
Time in home (years) 2.9 (2.7) 2.5 (2.4)
Number of medications
(T1)
7.1 (3.9) 8.8 (4.4)
Male 121 (27.2) 78 (20.5)
Size of home
Small 72 (16.2) 43 (11.3)
Medium 172 (38.7) 176 (46.2)
Large 201 (45.2) 162 (42.5)
Classification of home
Mixed 74 (16.6) 124 (32.6)
Nursing 75 (16.9) 0 ( 0.0)
Residential 296 (66.5) 257 (67.5)
Norfolk 221 (49.7) 187 (49.1)
Patient classification
Nursing 132 (29.7) 64 (16.8)
Residential 313 (70.3) 317 (83.2)
Dementia diagnosis 237 (53.3) 175 (45.9)
Care home characteristics n = 15 n = 15
Size of home
Small 5 (33.3) 5 (33.3)
Medium 6 (40.0) 7 (46.7)
Large 4 (26.7) 3 (20.0)
Classification of home
Mixed 2 (13.3) 3 (20.0
Nursing 2 (13.3) 0 (0.0)
Residential 11 (73.3) 12 (80.0)
Norfolk 8 (53.3) 7 (46.7)
aT0 = Time of allocation and represents the number of falls in previ-
ous 6 months from allocation date.
bT1 = Time of first intervention visit or equivalent in control homes.
Table 2 Effectiveness results - intention-to-treat analysis
Control Intervention
Rate ratio P-valueN Mean (SD) or N (%) N Mean (SD) or N (%)
Falls (per annum) 445 3.00 (5.49) 381 3.35 (8.30) 1.02 (0.74, 1.39) 0.910
HES admission (per annum) 445 0.72 (2.09) 381 0.88 (2.01) 1.19 (0.86, 1.64) 0.286
STOPP criteria T2a 405 0.80 (1.08) 352 0.71 (1.00) 0.85 (0.71, 1.01) 0.060
STOPP criteria T3b 330 0.85 (1.26) 283 0.69 (0.93) 0.82 (0.67, 1.00) 0.046
Time until death N (%) 445 153 (34.4) 381 125 (32.8) 0.98 (0.72, 1.31)b 0.868
aT2 = six month time period from first intervention (or equivalent in control homes) to second intervention.
bT3 = six month period from second intervention (or equivalent in control homes) to end of study.
cHazard ratio.
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are, however, multi-factorial in nature and require complex
interventions as they are also related to the ergonomics of
the care home environment and physical frailty of the care
home population,[27] consequently it may not be appropri-
ate to expect a single intervention focussed on medication
to have a significant impact on falls. It may also be that
periodic review every 6 months is not sufficient as benefits
of the review are lost as a resident’s health status changes
and any prescribing changes may be reversed.
Furthermore, there is growing interest in measures to
support the appropriateness of prescribing and it should
be noted that this study did not use the STOPP criteria
to aid clinical decisions, it was only used as an outcome
measure. Recent evidence suggests using prescribing
appropriateness tools may be able to demonstrate patient
benefit.[28] Incorporating these tools into prescribing soft-
ware may provide a cost-effective approach to improve
prescribing, but as stated above will not address the other
important aspects of effectively managing medicines in a
care home setting.
In light of the current COVID-19 pandemic, the
micro-costing of this intervention[20] should help deci-
sion-makers in planning care home medicines optimisa-
tion services. With recent advances in and adoption of
technology, approximately 10% of the intervention costs
could be reduced with remote access to clinical records
and video conferencing.[20] More frequent pharmacy and
medicine support, utilising pharmacists with prescribing
qualifications could further help optimise the clinical and
cost-effectiveness of this type of intervention.
Future studies in care home medicine management
should investigate simpler models involving fewer person-
nel, and a more holistic pharmacist role, encompassing all
aspects of prescribing and medicine delivery.
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